REGENXBIO Join Forces with Nippon Shinyaku to Develop and Commercialize RGX-121 and RGX-111 for Mucopolysaccharidosis (MPS)
Shots:
- REGENXBIO & Nippon have partnered to develop RGX-121 (Hunter syndrome; FDA’s accelerated approval expected in late 2025, with ongoing rolling BLA filing) & RGX-111 (P-I/II study for Hurler syndrome) in the US & Asia. The closing is expected in Q1’25
- REGENXBIO will get $110M upfront, ~$700M milestones ($40M development & regulatory + $660M sales) plus net-sales-based double-digit royalties in the US & Asia. It also retains all rights on the sale of RGX-121’s PRV, upon approval
- Furthermore, REGENXBIO will handle future development, manufacturing of the drugs for clinical & commercial use (US & Asia) as well as gains right to develop & commercialize them outside of the US & Asia. Nippon will market them in the US & Asia
Ref: Regenxbio | Image: Regenxbio & Nippon Shinyaku
Related News:- AbbVie and Simcere Zaiming Collaborate to Develop SIM0500 for Treating Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
